JP2019526571A5 - - Google Patents

Download PDF

Info

Publication number
JP2019526571A5
JP2019526571A5 JP2019511720A JP2019511720A JP2019526571A5 JP 2019526571 A5 JP2019526571 A5 JP 2019526571A5 JP 2019511720 A JP2019511720 A JP 2019511720A JP 2019511720 A JP2019511720 A JP 2019511720A JP 2019526571 A5 JP2019526571 A5 JP 2019526571A5
Authority
JP
Japan
Prior art keywords
compound
pharmaceutical composition
composition according
acid
neurotransmission
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019511720A
Other languages
English (en)
Japanese (ja)
Other versions
JP7066679B2 (ja
JP2019526571A (ja
Filing date
Publication date
Priority claimed from GBGB1614834.8A external-priority patent/GB201614834D0/en
Application filed filed Critical
Publication of JP2019526571A publication Critical patent/JP2019526571A/ja
Publication of JP2019526571A5 publication Critical patent/JP2019526571A5/ja
Application granted granted Critical
Publication of JP7066679B2 publication Critical patent/JP7066679B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019511720A 2016-09-01 2017-08-25 認知症の処置 Active JP7066679B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1614834.8A GB201614834D0 (en) 2016-09-01 2016-09-01 Treatment of dementia
GB1614834.8 2016-09-01
PCT/EP2017/071437 WO2018041739A1 (en) 2016-09-01 2017-08-25 Treatment of dementia

Publications (3)

Publication Number Publication Date
JP2019526571A JP2019526571A (ja) 2019-09-19
JP2019526571A5 true JP2019526571A5 (cg-RX-API-DMAC7.html) 2020-10-01
JP7066679B2 JP7066679B2 (ja) 2022-05-13

Family

ID=57139937

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019511720A Active JP7066679B2 (ja) 2016-09-01 2017-08-25 認知症の処置

Country Status (18)

Country Link
US (1) US10842796B2 (cg-RX-API-DMAC7.html)
EP (1) EP3506904B1 (cg-RX-API-DMAC7.html)
JP (1) JP7066679B2 (cg-RX-API-DMAC7.html)
KR (1) KR102559354B1 (cg-RX-API-DMAC7.html)
CN (1) CN109890391B (cg-RX-API-DMAC7.html)
AU (1) AU2017318333B2 (cg-RX-API-DMAC7.html)
CA (1) CA3034625A1 (cg-RX-API-DMAC7.html)
DK (1) DK3506904T3 (cg-RX-API-DMAC7.html)
ES (1) ES2847929T3 (cg-RX-API-DMAC7.html)
GB (1) GB201614834D0 (cg-RX-API-DMAC7.html)
HR (1) HRP20210162T1 (cg-RX-API-DMAC7.html)
MX (1) MX384442B (cg-RX-API-DMAC7.html)
MY (1) MY187564A (cg-RX-API-DMAC7.html)
PL (1) PL3506904T3 (cg-RX-API-DMAC7.html)
PT (1) PT3506904T (cg-RX-API-DMAC7.html)
SG (1) SG11201901125TA (cg-RX-API-DMAC7.html)
SI (1) SI3506904T1 (cg-RX-API-DMAC7.html)
WO (1) WO2018041739A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109384741B (zh) 2006-03-29 2023-01-06 维斯塔实验室有限公司 3,7-二氨基-10h-吩噻嗪化合物盐及其用途
DK2457904T3 (en) 2006-07-11 2015-01-12 Wista Lab Ltd Methods for the synthesis and / or purification of the compounds diaminophenothiazinium
EP4223297A3 (en) 2016-07-25 2023-11-15 WisTa Laboratories Ltd. Administration and dosage of diaminophenothiazines
FI3826639T3 (fi) 2018-07-26 2024-10-30 Wista Lab Ltd Diaminofenotiatsiinien optimoitu annostus populaatioille
WO2020048593A1 (en) 2018-09-05 2020-03-12 Wista Laboratories Ltd. Network methods for neurodegenerative diseases
GB201909493D0 (en) 2019-07-01 2019-08-14 Wista Lab Ltd Therapeutic interactions
GB201909454D0 (en) 2019-07-01 2019-08-14 Wista Lab Ltd Enhancers
GB201909506D0 (en) 2019-07-02 2019-08-14 Wista Lab Ltd Synaptopathies
MX2022013884A (es) * 2020-05-05 2022-11-30 Wista Lab Ltd Compuestos de metiltioninio para usarse en el tratamiento de hipoxemia.
GB202006659D0 (en) * 2020-05-05 2020-06-17 Wista Lab Ltd Therapeutic treatments
CA3257856A1 (en) 2022-05-31 2023-12-07 Wista Laboratories Ltd. TREATMENT OF NEURODEGENERATIVE DISORDERS USING COMPOUNDS CONTAINING METHYLTHIONINIUM (MT)
EP4342451A1 (en) * 2022-09-22 2024-03-27 Galenicum Health SLU Pharmaceutical compositions and manufacturing methods thereof
US20240115579A1 (en) * 2022-09-22 2024-04-11 Galenicum Health S.L.U. Pharmaceutical compositions and manufacturing methods thereof
US20240300940A1 (en) * 2023-02-21 2024-09-12 Prosetta Biosciences, Inc. Phenothiazinyl Compounds and Uses

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9506197D0 (en) 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
GB0101049D0 (en) 2001-01-15 2001-02-28 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
NZ536603A (en) * 2002-05-31 2007-06-29 Lundbeck & Co As H A combination of an NMDA-antagonist and acetylcholine esterase inhibitors for the treatment of Alzheimer's disease
PT1799662E (pt) 2004-09-23 2013-07-09 Wista Lab Ltd Métodos de síntese química e purificação de compostos de diaminofenotiazínio incluindo cloreto de metiltionínio (mtc)
EP2001556B1 (en) * 2006-03-29 2014-10-01 Wista Laboratories Ltd. Thioninium compounds and their use
CN109384741B (zh) * 2006-03-29 2023-01-06 维斯塔实验室有限公司 3,7-二氨基-10h-吩噻嗪化合物盐及其用途
FR2899107B1 (fr) * 2006-03-30 2008-06-13 Neurokin Entpr Unipersonnelle Utilisation de la (s)-roscovitine pour la fabrication d'un medicament
DK2457904T3 (en) 2006-07-11 2015-01-12 Wista Lab Ltd Methods for the synthesis and / or purification of the compounds diaminophenothiazinium
FR2903696B1 (fr) 2006-07-12 2011-02-11 Provence Technologies Procede de purification de composes diaminophenothiazium
US9034890B2 (en) * 2006-11-15 2015-05-19 Steven A. Rich Combined acetylcholinesterase inhibitor and quaternary ammonium antimuscarinic therapy to alter progression of cognitive diseases
DK2167095T3 (da) * 2007-06-19 2019-07-29 Wista Lab Ltd Phenothiazin-forbindelser til behandling af let kognitiv svækkelse
PL2205245T3 (pl) * 2007-10-03 2015-12-31 Wista Lab Ltd Zastosowanie terapeutyczne diaminofenotiazyn
SI2480540T1 (en) * 2009-09-24 2018-03-30 Wista Laboratories Ltd. Methionyl chloride pentahydrate, its preparation and pharmaceutical use
US8765742B2 (en) 2009-09-24 2014-07-01 Wista Laboratories Ltd. Crystalline methylthioninium chloride hydrates
AU2011358840B2 (en) * 2011-02-11 2017-05-04 TauRx Therapeutics Management Ltd Phenothiazine diaminium salts and their use
CN102936244B (zh) * 2012-12-04 2015-02-04 合肥工业大学 一种他克林-吩噻嗪异二联体类化合物及其制备方法

Similar Documents

Publication Publication Date Title
JP2019526571A5 (cg-RX-API-DMAC7.html)
JP6795517B2 (ja) 5−芳香族アルキニル基置換ベンズアミド系化合物並びにその製造方法、薬物組成物及び使用
JP7514534B2 (ja) 認知障害を処置するためのベンゾジアゼピン誘導体、組成物および方法
AU2014368961B2 (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
EP3606525B1 (en) Compositions for treating aging-associated impairments using ccr3-inhibitors
HRP20210162T1 (hr) Liječenje demencije
JP2015532295A5 (cg-RX-API-DMAC7.html)
JP2021503480A (ja) トラジピタントを用いた胃腸疾患の治療方法
EP3555100A1 (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
JP6023926B2 (ja) 認知症治療のための5−ht4受容体アゴニスト
JP2019521964A5 (cg-RX-API-DMAC7.html)
JP2023534189A (ja) Gabaaアルファ5アゴニストおよびsv2a阻害剤の組合せ物ならびに認知障害の処置において使用する方法
BRPI0808353B1 (pt) Usos de amidas do ácido 3-aril-3-hidróxi-2-amino-propiônico, amidas do ácido 3-heteroaril-3-hidróxi-2-amino-propiônico e compostos relacionados
US8598180B2 (en) Tetrahydroindolone derivatives for treatment of neurological conditions
JP2019518736A5 (cg-RX-API-DMAC7.html)
JP2018505899A (ja) ストレス誘発性p−tauを低下させるトリアゾロピリジン及びトリアゾロピリミジン
CN111050800B (zh) 血清素3受体激动剂对疼痛的治疗
BR112021004938A2 (pt) métodos e composições para tratamento de danos associados com o envelhecimento usando inibidores de ccr3
WO2016006621A1 (ja) Pgd2拮抗剤を含有するアレルギー性疾患に伴う症状の治療用医薬
JP4598674B2 (ja) 統合失調症治療剤
WO2012051601A2 (en) Heteroarylthio compounds
US20090156609A1 (en) Treatment of post-traumatic stress disorder with tetrahydroindolone arylpiperzaine compounds
JP2010530900A (ja) 中枢神経系活性を有する置換ピロリジン化合物
JP2011020957A (ja) アルツハイマー病治療薬
US20100227844A1 (en) Cannabinoid-1 receptor modulators useful for the treatment of alzheimer's disease